Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

4 treatments under study, led by Dalfampridineer 10 Mg

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 55/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results50% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (2)

Trial Status

Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02422940Phase 3TerminatedPrimary

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

NCT02271217Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

Showing all 2 trials

Research Network

Common Treatments

  • Dalfampridineer 10 Mg1
  • Dalfampridineer 75mg1
  • Dalfampridineer 10mg1
  • Dalfampridineer 75 Mg1

Active Sponsors

  • Acorda Therapeutics2

Top Investigators

Activity Timeline